WP
Walker Paul Edward
董事
BoardM
Monte Rosa Therapeutics, Inc.Bright Health Group Inc.Trevi Therapeutics, Inc.Trillium Therapeutics Inc.Metacrine, Inc.Genocea Biosciences, INC.Allakos Inc.Akouos, Inc.Mirum Pharmaceuticals, Inc.Savara IncKorro Bio, Inc.MBX Biosciences, Inc.NeueHealth, Inc.SpyGlass Pharma, Inc. 内部人交易记录
董事基于 4 个已确定 T+90 收益的买入信号。收益基准:公布次日的收盘价。
Discover the detailed record of transactions filed by Walker Paul Edward, 董事. Director active across 14 companies, notably Monte Rosa Therapeutics, Inc.. Aggregated, 17 filings have been published. Split: 6 buys · 2 sells. Total volume traded: €11.5m. History available since 17 November 2021. The latest transaction was disclosed on 10 March 2026 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Walker Paul Edward
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报17 总计
207,100 股@ US$11.1167.8% 占其流量Common StockSEC:0001193125-26-104714:0
1,619,240 股Common StockSEC:0001193125-26-046662:0
189,195 股@ US$0.01100.0% 占其流量Common StockSEC:0001193125-25-232143:0
2,760,860 股Common StockSEC:0000950170-25-072714:0
1,023,103 股Common StockSEC:0000950170-24-107544:0
17,857 股@ US$56.00100.0% 占其流量Common StockSEC:0000950170-24-047683:0
333,333 股@ US$3.00100.0% 占其流量Common StockSEC:0001209191-23-042804:0
2,000,000 股0Common StockSEC:0001209191-23-037366:0
4,294,207 股Common StockSEC:0001209191-22-059461:0
597,600 股@ US$5.02100.0% 占其流量Common StockSEC:0001209191-22-051146:0
5,931,843 股@ €0.0609100.0% 占其流量Common StockSEC:0001209191-22-032331:0
2,631,578 股@ US$1.90100.0% 占其流量Common StockSEC:0001209191-22-024322:0
37,570 股@ US$1.321100.0% 占其流量Common StockSEC:0001209191-21-071274:0
5,736,363 股0Common SharesSEC:0001209191-21-065762:0
1,851,852 股Common StockSEC:0001209191-21-061098:0
2,715,968 股Common StockSEC:0001209191-21-044050:0
5,864,718 股Common StockSEC:0001209191-21-044200:0
About Walker Paul Edward
Walker Paul Edward is an administrator, with 17 filings in total. In the 17 sampled recent filings, the activity is mainly acquisitions, with buys and sells recorded between 2021-06-30 and 2026-03-12, including Trevi Therapeutics, Inc., Allakos Inc., Korro Bio, Inc., Savara Inc and Metacrine, Inc.